Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 74
- Registration Number
- NCT01907880
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol)
- Conditions
- Interventions
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01802658
- Locations
- 🇫🇷
Institut Régional de Réadaptation Nancy, Nancy, France
🇫🇷Centre Mutualiste Neurologique Propara, Montpellier, France
🇫🇷Centre Bouffard - Vercelli CAP Cerbère, Cerbère, France
The Use of Zoledronic Acid to Complex Regional Pain Syndrome
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01788176
- Locations
- 🇧🇷
Centro de Pesquisa Clínica do Instituto de Medicina e Reabilitação do HCFMUSP, São Paulo, Brazil
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 643
- Registration Number
- NCT01732770
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Thar Pharmaceuticals, Inc
- Target Recruit Count
- 71
- Registration Number
- NCT01721993
- Locations
- 🇺🇸
Prism Clinical Research, St. Paul, Minnesota, United States
Zoledronic Acid in Cystic Fibrosis
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Papworth Hospital NHS Foundation Trust
- Registration Number
- NCT01702415
- Locations
- 🇬🇧
Papworth Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 9
- Registration Number
- NCT01679080
- Locations
- 🇩🇰
Department of Endocrinology M, Odense, Denmark
🇩🇰Department of endocrinology, Hvidovre, Denmark
🇩🇰Osteoporosis clinic; department of endocrinology and metabolism, Aarhus, Aarhus C, Denmark
Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT01675089
- Locations
- 🇧🇷
Hospital das Clinicas - Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01671774
- Locations
- 🇱🇻
Riga East University Hospital, LLC, Latvian Oncology Center, Riga, Latvia
🇩🇪Leipzig University Hospital, University Cancer Center (UCCL), Leipzig, Germany
🇩🇪Institut für Klinische Forschung, Krankenhaus Nordwest GmbH, Frankfurt, Hessen, Germany
Zoledronic Acid in Acute Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 16
- Registration Number
- NCT01642901
- Locations
- 🇺🇸
Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.